|
|
News for:
|
|
For this drug, our server compiled this detailed Chemical Profile.
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
|
Click the Chemical Profile link above for detailed information.
Visit Betterchem's Drug Index for
- Exclusivity
Patents and market exclusivity
- Drug Information
Prescribing and other
information
- DMFs
Type 2 drug master files
- Databases
Free access to database search
- 21 CFR
FDA regulations for this drug
- Federal Register
FR search results for this drug
- Drug Recalls
For Rx's using this API
|
|
|
| |
FDA Approval Activities for this Drug
Integrilin (eptifibatide) Injection, 20 mg/10 ml and 75 mg/ 100 ml, Injection, COR Therapeutics NDA 20-718 5/18 5/28/98 5/28/98 1/2/02
Integrilin Indications: 1. For the treatment of patients with acute coronary syndrome (UA/NQMI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction. 2. For the treatment of patients undergoing PCI. In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpont of death, new myocardial infarction, or need for urgent intervention.
Integrilin (eptifibatide) Injection, COR Therapeutics, NDA 20-718/S-002 9/20/99 9/24/99 9/24/99 7/5/01
Integrilin Indication:For the treatment of patients with acute coronary syndrome (UA/NQMI),
including patients who are to be managed medically and those undergoing
percutaneous coronary intervention (PCI). In this setting, Integrilin has
been shown to decrease the rate of a combined endpoint of death or new
myocardial infarction.
For the treatment of patients undergoing PCI. In this setting, Integrilin
has been shown to decrease the rate of a combined endpoint of death, new
myocardial infarction, or need for urgent intervention.
Integrilin (eptifibatide) Injection, COR Therapeutics, NDA 20-718/S-010 & S-13 EPTIFIBATIDE Injection 2MG/ML INTEGRILIN MILLENNIUM 020718 EPTIFIBATIDE Injection 75MG/100ML INTEGRILIN MILLENNIUM Integrilin (eptifibatide) Injection, Millennium Pharmaceuticals, Inc., Labeling Revision | Integrilin (eptifibatide) Injection, Millennium Pharma, Labeling Revision
Visit Betterchem's Drug Index for FDA's latest approval information.
|
|